- Home
- XTNT vs ADAP Comparison
XTNT vs ADAP Comparison
Compare XTNT & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTNT
- ADAP
- Stock Information
- Founded
- XTNT N/A
- ADAP 2008
- Country
- XTNT United States
- ADAP United Kingdom
- Employees
- XTNT N/A
- ADAP N/A
- Industry
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- XTNT Health Care
- ADAP Health Care
- Exchange
- XTNT Nasdaq
- ADAP Nasdaq
- Market Cap
- XTNT 60.9M
- ADAP 71.6M
- IPO Year
- XTNT N/A
- ADAP 2015
- Fundamental
- Price
- XTNT $0.50
- ADAP $0.20
- Analyst Decision
- XTNT Strong Buy
- ADAP Strong Buy
- Analyst Count
- XTNT 1
- ADAP 5
- Target Price
- XTNT $3.00
- ADAP $1.93
- AVG Volume (30 Days)
- XTNT 40.5K
- ADAP 2.5M
- Earning Date
- XTNT 03-06-2025
- ADAP 03-20-2025
- Dividend Yield
- XTNT N/A
- ADAP N/A
- EPS Growth
- XTNT N/A
- ADAP N/A
- EPS
- XTNT N/A
- ADAP N/A
- Revenue
- XTNT $117,267,000.00
- ADAP $178,032,000.00
- Revenue This Year
- XTNT $15.56
- ADAP N/A
- Revenue Next Year
- XTNT $22.39
- ADAP $56.87
- P/E Ratio
- XTNT N/A
- ADAP N/A
- Revenue Growth
- XTNT 28.44
- ADAP 195.34
- 52 Week Low
- XTNT $0.33
- ADAP $0.20
- 52 Week High
- XTNT $1.18
- ADAP $1.55
- Technical
- Relative Strength Index (RSI)
- XTNT 50.16
- ADAP 13.88
- Support Level
- XTNT $0.45
- ADAP $0.26
- Resistance Level
- XTNT $0.54
- ADAP $0.47
- Average True Range (ATR)
- XTNT 0.05
- ADAP 0.04
- MACD
- XTNT 0.00
- ADAP -0.02
- Stochastic Oscillator
- XTNT 63.64
- ADAP 1.53
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.